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Background
After more than 30 years, Ipilimumab was the first agent
which showed a survival benefit for the treatment of
metastatic melanoma. However, only about the 20% of
patients have a long-term survival benefit. The combina-
tion of ipilimumab with other therapies might improve
its efficacy.
A new phenomenon also known as abscopal effect refers
to a regression of metastatic lesions distant from the pri-
mary site of radiotherapy (RT). This systemic response is
observed in patients who received ipilimumab.
Here we reported the outcomes from patients treated
in the ipilimumab Italian expanded access program
(EAP) who received RT after ipilimumab progression.
Patients and methods
Patients with advanced melanoma who had received RT
after ipilimumab progression were eligible for analysis.
Radiotherapy was available upon physician request for
patients who failed ipilimumab therapy and for whom
no other therapeutic options were available.
Results
21 out of 95 patients treated with ipilimumab in the Italian
EAP were eligible for the analysis. The median age was of
58 years (range 21-77); The progression free survival (PFS)
from ipilimumab treatment was 4 months (range 3-6),
while the time from the end of treatment with ipilimumab
and RT was of 5 months (range 4-8).
RT was performed on brain in 13 (62%) patients: 8
were treated with whole-brain RT and 5 patients with
stereotactic RT. Other RT treatment included bone,
metastatic distant lymph nodes, sub-cutaneous metas-
tasis, spinal cord metastatis. The median doses of
radiation was of 30 Gy (range 30-50). A local response
to RT was detected in 13 patients (62%) while 8
patients (38%) did not show any local regression. The
abscopal response has been detected in 11/21 (52%)
patients: in details, we observed 9 abscopal partial
response (42,8%), 2 abscopal stable disease (9,6%), and
10 progression (47,6%). The median of occurrence of
the abscopal response was of 1 month (range 1-4). The
median overall survival (OS) for all the 21 patients was
of 13 months (range 6-26). The median OS for
patients with and without abscopal responses was
respectively of 22.4 months (range 2,5-50,3) and 8,3
months (range 7,6-9.0). 11 (84,6%) out of 13 patients
with local response showed an abscopal effect.
Conclusions
The RT after ipilimumab treatment may be an option for
further potentiate its effect. Local response to RT might
be predictive for the abscopal response and outcome.
Further studies are warranted in this field to better
understand and define the role of RT in combination or
sequencing with ipilimumab treatment.
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